Identification of a novel water-soluble activator of wild-type and F508del CFTR: GPact-11a

European Respiratory Journal

Volumn 36, Issue 2, 2010, Pages 311-322

  Bertrand, J ^a   Boucherle, B ^c   Billet, A ^a   Melin Heschel, P ^a   Dannhoffer, L ^a   Vandebrouck, C ^a   Jayle, C ^b   Routaboul, C ^c   Molina, M C ^c   Decout J L ^c   Becq, F ^a   Norez, C ^a  

^a UNIVERSITÉ DE POITIERS   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c Université Joseph Fourier   (France)

Author keywords

Airway epithelial cells; Cystic fibrosis; Epithelial ion transports; F508del CFTR activator; Knock out mice; Methylglyoxal 9 propyladenine

Indexed keywords

ATROPINE; CHLORIDE CHANNEL; CYCLIC AMP; F508DEL CFTR ACTIVATOR; FORSKOLIN; GRENOBLE POITIERS CFTR ACTIVATOR 11A; HETEROCYCLIC COMPOUND; IODINE 125; METHYLGLYOXAL 9 PROPYLADENINE; NEW DRUG; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; WATER;

AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; CHO CELL; CYSTIC FIBROSIS; DELETION MUTANT; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; LUNG LOBECTOMY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SALIVARY GLAND; SOLUBILITY; STRUCTURE ACTIVITY RELATION;

ADENINE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; IODIDES; LUNG; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; PATCH-CLAMP TECHNIQUES; PURINES; PYRIMIDINES; SALIVA; SOLUBILITY; WATER;

EID: 77955647867     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00122509     Document Type: Article

References (41)

1. Anderson MP, Berger HA, Rich DP, et al. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 1991; 67: 775-784.
2. Gray MA, Plant S, Argent BE. cAMP-regulated whole cell chloride currents in pancreatic duct cells. Am J Physiol 1993; 264: C591-C602.
3. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003; 361: 681-689.
4. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999; 79: Suppl. 1, S23-S45.
5. Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 1991; 354: 526-528.
6. Becq F. On the discovery and development of CFTR chloride channel activators. Curr Pharm Des 2006; 12: 471-484.
7. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009; 8: 153-171.
8. Bebok Z, Collawn JF, Wakefield J, et al. Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o- airway epithelial monolayers. J Physiol 2005; 569: 601-615.
9. Yang H, Shelat AA, Guy RK, et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 2003; 278: 35079-35085.
10. Olesen SP, Munch E, Moldt P, et al. Selective activation of Ca(2+)-dependent K+ channels by novel benzimidazolone. Eur J Pharmacol 1994; 251: 53-59.
11. Hwang TC, Wang F, Yang IC, et al. Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 1997; 273: C988-C998. (Pubitemid 27422179)
12. Wang F, Zeltwanger S, Hu S, et al. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol 2000; 524: 637-648.
13. Routaboul C, Norez C, Melin P, et al. Discovery of alpha- aminoazaheterocycle- methylglyoxal adducts as a new class of high-affinity inhibitors of cystic fibrosis transmembrane conductance regulator chloride channels. J Pharmacol Exp Ther 2007; 322: 1023-1035.
14. Routaboul C, Dumas L, Gautier-Luneau I, et al. New stereoselective reaction of methylglyoxal with 2-aminopyridine and adenine derivatives: formation of imino acid-nucleic base derivatives in water under mild conditions. Chem Commun (Camb) 2002; 10: 1114-1115.
15. Noel S, Faveau C, Norez C, et al. Discovery of pyrrolo[2,3-b] pyrazines derivatives as submicromolar affinity activators of wild type, G551D, and F508del cystic fibrosis transmembrane conductance regulator chloride channels. J Pharmacol Exp Ther 2006; 319: 349-359.
16. Antigny F, Norez C, Becq F, et al. Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium 2008; 43: 175-183.
17. Dechecchi MC, Nicolis E, Norez C, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros 2008; 7: 555-565.
18. Lipecka J, Norez C, Bensalem N, et al. Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network. J Pharmacol Exp Ther 2006; 317: 500-505.
19. Melin P, Thoreau V, Norez C, et al. The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein. Biochem Pharmacol 2004; 67: 2187-2196.
20. Melin P, Hosy E, Vivaudou M, et al. CFTR inhibition by glibenclamide requires a positive charge in cytoplasmic loop three. Biochim Biophys Acta 2007; 1768: 2438-2446.
21. Norez C, Heda GD, Jensen T, et al. Determination of CFTR chloride channel activity and pharmacology using radiotracer flux methods. J Cyst Fibros 2004; 3: Suppl. 2, 119-121.
22. Norez C, Antigny F, Noel S, et al. A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a noncystic fibrosis-like phenotype. Am J Respir Cell Mol Biol 2009; 41: 217-225.
23. Wu DZ, Yuan JY, Shi HL, et al. Palmatine, a protoberberine alkaloid, inhibits both Ca(2+)- and cAMP-activated Cl(-) secretion in isolated rat distal colon. Br J Pharmacol 2008; 153: 1203-1213.
24. Best JA, Quinton PM. Salivary secretion assay for drug efficacy for cystic fibrosis in mice. Exp Physiol 2005; 90: 189-193.
25. Noel S, Strale PO, Dannhoffer L, et al. Stimulation of salivary secretion in vivo by CFTR potentiators in Cftr+/+ and Cftr-/- mice. J Cyst Fibros 2008; 7: 128-133.
26. Ma T, Thiagarajah JR, Yang H, et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002; 110: 1651-1658.
27. Muanprasat C, Sonawane ND, Salinas D, et al. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol 2004; 124: 125-137.
28. Schultz BD, Singh AK, Devor DC, et al. Pharmacology of CFTR chloride channel activity. Physiol Rev 1999; 79: Suppl. 1, S109-S144.
29. Norez C, Noel S, Wilke M, et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the α-glucosidase inhibitor miglustat. FEBS Lett 2006; 580: 2081-2086.
30. Casals T, Pacheco P, Barreto C, et al. Missense mutation R1066C in the second transmembrane domain of CFTR causes a severe cystic fibrosis phenotype: study of 19 heterozygous and 2 homozygous patients. Hum Mutat 1997; 10: 387-392.
31. Fanen P, Labarthe R, Garnier F, et al. Cystic fibrosis phenotype associated with pancreatic insufficiency does not always reflect the cAMP-dependent chloride conductive pathway defect. Analysis of C225R-CFTR and R1066C-CFTR. J Biol Chem 1997; 272: 30563-30566.
32. Mercier B, Lissens W, Novelli G, et al. Identification of eight novel mutations in a collaborative analysis of a part of the second transmembrane domain of the CFTR gene. Genomics 1993; 16: 296-297.
33. Loo TW, Bartlett MC, Wang Y, et al. The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants. Biochem J 2006; 395: 537-542.
34. Galietta LJ, Moran O. Identification of CFTR activators and inhibitors: chance or design? Curr Opin Pharmacol 2004; 4: 497-503.
35. Kochegarov AA. Pharmacological modulators of voltage-gated calcium channels and their therapeutical application. Cell Calcium 2003; 33: 145-162.
36. Whiting PJ. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today 2003; 8: 445-450.
37. Al Nakkash L, Hwang TC. Activation of wild-type and ΔF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms. Pflugers Arch 1999; 437: 553-561.
38. Wang F, Zeltwanger S, Yang IC, et al. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen Physiol 1998; 111: 477-490.
39. Bulteau L, Derand R, Mettey Y, et al. Properties of CFTR activated by the xanthine derivative X-33 in human airway Calu-3 cells. Am J Physiol Cell Physiol 2000; 279: C1925-C1937.
40. Haws CM, Nepomuceno IB, Krouse ME, et al. DF508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am J Physiol 1996; 270: C1544-C1555.
41. Melin P, Norez C, Callebaut I, et al. The glycine residues G551 and G1349 within the ATP-binding cassette signature motifs play critical roles in the activation and inhibition of cystic fibrosis transmembrane conductance regulator channels by phloxine B. J Membr Biol 2005; 208: 203-212.